Research programme: anti-infectives - Novozymes A/S
Alternative Names: Eurocin; Munumbicin A; Munumbicin B; Munumbicin D; Munumbicins - Novozymes; Novicidin; Novispirin; Novispirins series - Novozymes; NZ 1000 series - Novozymes; NZ 1001; NZ 2000 series - Novozymes; Plectasin; Plectasins series - Novozymes; Streptomycins - NovozymesLatest Information Update: 17 Aug 2012
At a glance
- Originator Novozymes A/S
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Gram-negative infections; Gram-positive infections
Highest Development Phases
- Discontinued Gram-negative infections; Gram-positive infections
Most Recent Events
- 27 Oct 2011 Discontinued - Preclinical for Gram-negative infections in Denmark (unspecified route)
- 27 Oct 2011 Discontinued - Preclinical for Gram-positive infections in Denmark (unspecified route)
- 27 Oct 2011 Research programme: anti-infectives - Novozymes A/S is available for licensing as of 27 Oct 2011. http://www.novozymes.com